Clinical trials
Leukemia, Hairy Cell trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
10 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2021 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 10 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cambridge Antibody Technology | 1 |
| Garden State Cancer Center at the Center for Molecular Medicine and Immunology | 1 |
| Institut Català d'Oncologia | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
| Medical College of Wisconsin | 1 |
| Milton S. Hershey Medical Center | 1 |
| Power Life Sciences Inc. | 1 |
| The Cleveland Clinic | 1 |
| University Hospital, Strasbourg, France | 1 |
| University of Glasgow | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Hairy Cell | 10 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Burkitt Lymphoma | 6 |
| Lymphoma, B-Cell, Marginal Zone | 6 |
| Lymphoma, Follicular | 6 |
| Lymphoma, Mantle-Cell | 6 |
| Lymphoma, Non-Hodgkin | 6 |
| Blast Crisis | 5 |
| Hodgkin Disease | 5 |
Trials
Showing 76 to 10 of 10. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.